Table 1 Demographics of the study participants.

From: CC-chemokine ligand 18, CXC motif chemokine 13 and osteopontin as biomarkers of silicosis and asbestosis: a prospective observational study

 

Silicosis

Asbestosis

HCs

P-value*

N

231

163

118

 

Male: Female

204:27

55:108

79:39

<0.001

Age (yrs)

63.0 ± 12.5

73.2 ± 8.0

60.0 ± 11.2

<0.001

BMI (kg/m2)

24.3 ± 4.0

25.7 ± 4.2

25.5 ± 3.1

0.002

Smoking status

Current smoker (n)

116

32

25

<0.001

Cumulative pack-yrs, median(IQR)

17.8(1.8–41.3)

15.0(1.5–50.0)

13.0(0.5–23)

0.006

Ex-smokers (n)

34

27

19

<0.001

Non-smokers (n)

81

104

74

<0.001

Years of exposure to crystalline silica/asbestos(yrs)

13.0(8.0–20.0)

15 (6.0–27.0)

NA

0.539

Pulmonary function values

FVC (predicted %)

68.7 ± 42.4

71.5 ± 21.6

83.7 ± 16.4

<0.001

FEV1 (predicted %)

56.8 ± 40.1

68.3 ± 21.8

81.6 ± 11.3

<0.001

FEV1/FVC (%)

69.2 ± 23.6

83.3 ± 21.1

83.8 ± 10.6

<0.001

TLC (predicted %)

72.4 ± 39.4

76.2 ± 21.4

86.7 ± 9.2

0.002

DLCO SB (predicted %)

73.7 ± 24.4

63.8 ± 20.7

80.3 ± 8.7

0.010

PH

49(21.2%)

6(3.7%)

0

<0.001

COPD

63(27.3%)

27(16.5%)

0

0.012

Respiratory failure

35(15.3%)

20(12.3%)

0

<0.001

Stages of pneumoconiosis

Stage I (n)

68

98

NA

0.000

Stage II (n)

61

47

NA

0.356

Stage III (n)

102

18

NA

0.000

  1. Data were presented as n, percentage, or mean ± SD.
  2. Abbreviations: BMI, body mass index; HCs, healthy controls; FVC, forcedvital capacity; FEV1 ,forced expiratory volume in first second; DLCOSB,diffusing capacity of the lung for carbon monoxide; PH, pulmonaryhypertension; COPD,chronic obstructive pulmonary disease; NA, notavailable.
  3. * P-values were computed by chi-square test for sex and smoking status,one-way analysis of variance for age, BMI, FVC, FEV1, FEV1/FVC ratio,DLCOSB. t test was used to estimate stages of pneumoconiosis.
Back to article page